Table 3.
Clinical trials for HPV-associated cancer
| Vaccine | Antigen(s) | Phase | Cancer |
|---|---|---|---|
|
ADXS11-001: |
HPV-16 |
I |
Cervical cancer |
|
Lm secreting fusion to LLO-HPV-16 E7 protein (Lm-LLO-E7) |
E7 |
I |
HPV- oropharyngeal cancer |
| |
II |
Recurrent cervical carcinoma |
|
|
TA-HPV: Recombinant vaccinia virus expressing E6 and E7 from both HPV-16 and HPV-18 |
E6 and E7 of HPV16 and HPV-18 E6 |
I |
Stage Ib and IIa cervical cancer |
| |
I/II |
Advanced cervical cancer |
|
| |
II |
Stage Ib and IIa cervical cancer |
|
|
PADRE peptide linked to E7 Lipopeptide |
HPV-16 E7 |
I |
Cervical cancer |
|
HPV-16 E7 epitopes emulsified in Montanide ISA-51 adjuvant |
HPV-16 E7 |
I/II |
Cervical cancer |
|
13 overlapping long peptides covering whole E6 and E7 sequences of HPV 16 plus Montanide ISA-51 adjuvant |
HPV-16 E6 and E7 |
I |
Advanced cervical cancer stage Ib1 cervical cancer |
| |
II |
|
|
|
DC pulsed with HPV-16 E7 |
HPV-16 E7 |
I |
Recurrent cervical cancer |
| pNGVL4a-Sig/E7/Hsp70: DNA plasmid expressing mutated HPV-16 E7 fused to Sig and Hsp70 | HPV-16 E7 | I | Advanced HNSCC |
Note: Abbreviations are as in the text.